Search results
Results from the WOW.Com Content Network
Tay–Sachs disease, which can present as a fatal illness of children that causes mental deterioration prior to death, was historically extremely common among Ashkenazi Jews, [19] with lower levels of the disease in some Pennsylvania Dutch, Italian, Irish Catholic, and French Canadian descent, especially those living in the Cajun community of ...
Ashkenazi Jews have been screened as Tay–Sachs carriers since carrier testing began in 1971. Since the 1970s, many Jewish communities have embraced genetic screening, and in 1971, Israel became the first country to offer free genetic screening [1] and counseling for Tay–Sachs disease and other diseases, leading to international discussion about the proper scope of genetic testing.
Dor Yeshorim (Hebrew: דור ישרים) also called Committee for Prevention of Jewish Genetic Diseases, is a nonprofit organization that offers genetic screening to members of the Jewish community worldwide. Its objective is to minimize, and eventually eliminate, the incidence of genetic disorders common to Jewish people, such as Tay–Sachs ...
Taken together, sphingolipidoses have an incidence of approximately 1 in 10,000, but substantially more in certain populations such as Ashkenazi Jews. Enzyme replacement therapy is available to treat mainly Fabry disease and Gaucher disease, and people with these types of sphingolipidoses may live well into adulthood. The other types are ...
Researchers suggest their study challenges the previous view that disease-related variants associated with Ashkenazi Jewish populations only became more common in the past 600 years.
Tay–Sachs disease. Enzyme assay testing was especially effective among Ashkenazi Jews because fewer pseudodeficiency alleles are found in this population, as compared with the general population. Carrier screening has not been as reliable in the general population. [1] [2] Metachromatic leukodystrophy.
Although no cure for Tay–Sachs disease has been found, antenatal genetic screening has virtually eliminated the disease in the Ashkenazi Jewish population in both the United States and Israel. In 1979, Kaback served on the first National Institutes of Health (NIH) panel to recommend antenatal diagnosis in cases where a couple might be at risk ...
The condition known as Tay–Sachs disease is named after Sachs along with English ophthalmologist Waren Tay. Tay first described the red spot on the retina of the eye in 1881, while Sachs provided a more comprehensive description of the disease, and in 1887 noted its higher occurrence in Ashkenazi Jews from Eastern Europe. [2] [3]